Allergy Therapeutics: Record sales, strong cash balance, portfolio diversification

23rd September 2020

Preliminary Results for the year ended 30 June 2020

Record level of pre R&D operating profit supported by robust sales and operational efficiency
Strong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully funded
Exclusive licencing agreement signed for further virus like particle(VLP) candidates

Allergy Therapeutics plc (AIM: AGY) has today announced an impressive all round set of results, with record sales despite the global uncertainty and £37m on the balance sheet which is enough to fund the Grass MATA MPL Phase III programme and the Phase I Peanut Trial. Perhaps most significantly, the Group has moved outside allergy treatments by exploring the potential of VLP technologies to treat solid cancer tumours and asthma (amongst other conditions).

We interviewed CEO Manuel Llobet, CFO Nick Wykeman and Head of Business Development Alan Bullimore below, who outlines the progress made in the period and provide more detail on the additions to the Group’s portfolio.

Allergy Therapeutics Investors Video

CEO Manuel Llobet on Five Minute pitch TV updating investors on the progress of their allergy vaccines

Click here to view Allergy Therapeutics investor video